tinea%20capitis
TINEA CAPITIS
Tinea capitis  is a contagious dermatophytosis affecting the hair shaft and follicles of the scalp, eyebrows and eyelashes.
It is most common in the crowded areas as infection originates from contact with a pet or an infected person and asymptomatic carriage persists indefinitely.
It primarily affects children 3-7 years of age.
The causative agents are the genus Trichophyton and Microsporum.
Cardinal clinical feature is the combination of inflammation with hair breakage and loss.

Patient Education

  • Educate patient regarding contagiousness of the disease
    • Identify & treat asymptomatic carriers in household members to avoid disease transmission
    • Avoid sharing hats, combs, towels, toys w/ an affected individual
    • Treat or remove an animal or pet infected w/ M canis
    • Disinfect belongings of infected patients such as hairbrushes, combs, beddings, etc
  • Children may attend school while being treated
  • Follow-up visits are needed for assessment of treatment response
    • Treatment course may be extended if patient is still symptomatic after completion of therapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Apr 2013
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
2 days ago
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Jairia Dela Cruz, 16 Aug 2017
Daily administration of two probiotic strains, Bifidobacterium animalis subsp lactis and Lactobacillus rhamnosus, does not appear to be effective in the prevention of respiratory or gastrointestinal infections in infants, as shown in the ProbiComp* study.
4 days ago
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.